在B细胞急性淋巴细胞白血病中,DNTT介导的DNA损伤反应驱动了inotuzumab臭加米辛的耐药性
Carolin S Escherich1,2, Takaya Moriyama1, Zhenhua Li1
1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Blood
|January 10, 2025
概括
在B细胞急性淋巴细胞白血病 (B-ALL) 患者中,DNA核样脱氧转移酶 (DNTT) 损失驱动了对伊诺图祖马布臭胺 (InO) 治疗的耐药性. DNTT下调会损害DNA损伤反应,为个性化B-ALL治疗提供潜在的生物标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 伊诺图祖马布奥佐加米辛 (InO) 在B细胞急性淋巴细胞白血病 (B-ALL) 中显示出有效性.
- 在INO反应的患者间变异性表明潜在的遗传因素.
- InO抗性的遗传基础在很大程度上是未知的.
研究的目的:
- 确定影响B-ALL对InO反应的遗传因素.
- 为了阐明 InO 电阻的机制.
- 评估DNTT作为INO治疗的潜在生物标志物.
主要方法:
- 全基因组的CRISPR屏幕用于识别耐药性基因.
- 关于DNA损伤反应,细胞循环和细胞亡的机制研究.
- 单细胞RNA测序用于白血病内异质性分析.
- 对儿童瘤组试验AALL1621.2的患者数据的分析.
- 在体内研究使用患者衍生异种移植模型.
主要成果:
- 鉴定出DNA核脱氧转移酶 (DNTT) 的损失是InO耐药性的主要驱动因素.
- DNTT下调减弱了因诺诱导的DNA损伤,细胞循环停止和细胞亡.
- 在ALL爆发中,DNTT表达水平与ex vivo InO灵敏度相关.
- 在INO治疗后的患者中,在残留的B-ALL爆发中观察到DNTT下调.
- 在体内证实了DNTT-low爆发的选择.
结论:
- DNTT是白血病中卡利希胺素反应的关键调节剂.
- 通过损害细胞损伤反应,DNTT下调赋予了对InO的抗性.
- DNTT表达作为一个潜在的生物标志物用于个性化 B-ALL.的 InO 治疗.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cytotoxic T Cells-mediated Immune Response
841
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
841


